SCHEMBL22653510

SCHEMBL22653510

C=C(C(N)=O)c1cc(N2CCN(CC)CC2)ccc1Nc1cc(NC(=O)N(C)c2c(Cl)c(OC)cc(OC)c2Cl)ncn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 17/20 0.62
FGFR4 P22455 10/20 0.62
FGFR2 P21802 5/20 0.62
FGFR3 P22607 5/20 0.62
JAK2 O60674 2/20 0.60
ABL1 P00519 2/20 0.60
INSR P06213 2/20 0.60
LCK P06239 2/20 0.60
FYN P06241 2/20 0.60
YES1 P07947 2/20 0.60
LYN P07948 2/20 0.60
RET P07949 2/20 0.60
MET P08581 2/20 0.60
ROS1 P08922 2/20 0.60
KIT P10721 2/20 0.60
SRC P12931 2/20 0.60
BRAF P15056 2/20 0.60
PDGFRA P16234 2/20 0.60
FLT1 P17948 2/20 0.60
TYK2 P29597 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18153617 0.90 FGFR1 (0.77) FGFR1FGFR4FGFR2FGFR3JAK2
SCHEMBL19900693 0.85 FGFR1 (0.81) FGFR1FGFR4FGFR2FGFR3
SCHEMBL22653511 0.81 FGFR1 (0.60) FGFR1FGFR4FGFR2FGFR3JAK2
SCHEMBL2014816 0.80 FGFR1 (0.83) FGFR1FGFR4FGFR2FGFR3JAK2
SCHEMBL16654071 0.79 FGFR1 (0.79) FGFR1FGFR4FGFR2FGFR3JAK2
SCHEMBL2014529 0.79 FGFR1 (0.81) FGFR1FGFR4FGFR2FGFR3JAK2
SCHEMBL2012965 0.78 FGFR1 (0.79) FGFR1FGFR4FGFR2FGFR3JAK2
SCHEMBL22171996 0.77 FGFR4 (0.84) FGFR1FGFR4FGFR2FGFR3JAK2
SCHEMBL29554791 0.77 FGFR1 (0.68) FGFR1FGFR4FGFR2FGFR3JAK2
SCHEMBL18162423 0.77 FGFR1 (0.83) FGFR1FGFR4FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021231928-A1 A METHOD FOR TREATING CANCER WITH AN ORAL DOSAGE FORM OF AN FGFR4 INHIBITOR EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-18 WO claimed
EP-3737377-A1 COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA Eisai R&D Management Co., Ltd. (JP) 2020-11-18 EP claimed